Røde blodceller

Polycytemia vera

Ulike blodsykdommer

Pasientinformasjon

Blod

Kliniske kapitler

Håndboken

Norsk Elektronisk Legehåndbok

Hva er polycytemia vera?

Årsaker

Symptomer

Diagnosen

Behandling

Prognose

Å leve med polycytemia vera

Vil du vite mer?

--&gt; https://www.helsedirektoratet.no/tema/kreft/maligne-blodsykdommer

Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne blodsykdommer. Myeloproliferative neoplasier. 2012. Sist faglig oppdatert 23. des 2021. 

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 Dec;95(12):1599-1613. PMID: 32974939. 

Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017 Feb 9;129(6):667-679. PMID: 28028029. 

--&gt; http://www.bloodjournal.org/cgi/search?volume=127&amp;firstpage=2391

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood 2016; 127(20): 2391-405. 

Tefferi A, Guglielmelli P, Lasho TL et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020 Apr;189(2):291-302. PMID: 31945802. 

--&gt; http://dx.doi.org/10.1038/s41375-018-0207-9

Stein BL, Oh ST, Berenzon D, et al. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. J Clin Oncol 2015 ;33(33): 3953-60. DOI: 10.1038/s41375-018-0207-9 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Br J Haematol [ta]+AND+172[vol]+AND+337[page]

McMullin MF, Wilkins BS, Harrison CN. Management of polycythaemia vera: a critical review of current data. Br J Haematol 2016; 172(3): 337-49. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Hematol Oncol Clin North Am [ta]+AND+25[vol]+AND+261[page]

Harrison CN, Robinson SE. Myeloproliferative disorders in pregnancy. Hematol Oncol Clin North Am 2011; 25(2): 261-75. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Ann Hematol[ta]+AND+98[vol]+AND+1071[page]

Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98(5):1071-1082. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Blood[ta]+AND+126[vol]+AND+1762[page]

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNa-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015; 126(15): 1762-1769. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Leuk Res[ta]+AND+54[vol]+AND+73[page]

Gowin K, Thapaliya P, Samuelson J, et al. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res. 2017; 54: 73-77. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=N Engl J Med[ta]+AND+372[vol]+AND+426[page]

Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015; 372(5): 426-35. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=Lancet Oncol [ta]+AND+18[vol]+AND+88[page]

Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 2017; 18: 88-99. 

--&gt; Ahlstrand E, Andersen CL, Andreasson B et al. Nordic care program for patients with Essential Thrombocythemia, Polycythemia Vera. 4th version March 2017. Stockholm: Nordic MPD Study Group; 2017.
Ahlstrand E, Andersen CL, Andreasson B et al. Nordic care program for patients with Essential Thrombocythemia, Polycythemia Vera. 4th version March 2017. Stockholm: Nordic MPD Study Group; 2017.
http://www.nmpn.org/index.php/guidelines

Ahlstrand E, Andersen CL, Andreasson B et al. Nordic care program for patients with Essential Thrombocythemia, Polycythemia Vera. 4th version March 2017. Stockholm: Nordic MPD Study Group; 2017. and Primary Myelofibrosis 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=J Clin Oncol [ta]+AND+29[vol]+AND+761[page]

Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29(6): 761-70. 

Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018; 93: 1474–1484. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=AJCP  Am J Clin Pathol [ta]+AND+146[vol]+AND+408[page]

Busque L, Porwit A, Day R, et al. Laboratory Investigation of Myeloproliferative Neoplasms. AJCP Am J Clin Pathol 2016; 146: 408-422. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=N Engl J Med[ta]+AND+368[vol]+AND+22[page]

Marchioli R, Finazzi G, Specchia G, et al; CYTOPV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013; 368(1): 22-33. 